StockData
Lexicon Pharmaceuticals, Inc. logo

Lexicon Pharmaceuticals, Inc. (LXRX) stock

LXRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/3087% above fair value
$1.78+0.03 (+1.71%)

Close on Nov 17, 2026Market cap $792.02MP/E –Yield –

Lexicon Pharmaceuticals price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Lexicon Pharmaceuticals's price to sales ratio was 20.2× on Nov 11, 2026, against 7.4× a year earlier. Over the last 5 years it ranged from 0.4× to 457.3×, with a median of 13.3×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202620.2×+14.2
2025Dec 31, 20255.9×−35.1
2024Dec 31, 202441.1×−372.0
2023Nov 30, 2023413.1×+314.7
2021Oct 29, 202198.4×+86.9
2020Dec 31, 202011.5×+10.1
2019Dec 31, 20191.4×−7.4
2018Dec 31, 20188.8×−4.1
2017Dec 29, 201712.8×+5.0
2016Dec 30, 20167.9×−46.5
2015Dec 31, 201554.4×−113.8
2014Dec 31, 2014168.2×−217.2
2012May 31, 2012385.4×–

More Lexicon Pharmaceuticals figures

See a number that looks wrong?